Navigation Links
FDA Approves New Product to Treat Von Willebrand Disease

The U.S. Food and Drug Administration (FDA) today announced the approval of Antihemophilic Factor/von Willebrand Factor Complex (Human), Alphanate. //The product is approved for patients undergoing surgery or invasive procedures with von Willebrand disease (vWD) in whom the hormone desmopressin is either ineffective or contraindicated. It is not approved for patients with severe vWD (Type 3) who are undergoing major surgery. The disease is the most common inherited bleeding disorder, affecting about one percent of the U.S. population.

Alphanate is the first biologic product approved for treatment of surgical and invasive procedures in patients with vWD. Alphanate is already approved for the prevention and control of bleeding in patients with Factor VIII deficiency due to hemophilia A or acquired Factor VIII deficiency.

"This approval is an important advance for patients and their surgeons, providing them access to a proven preventive therapy that can make needed surgery possible and safer," said Jesse L. Goodman, M.D., MPH, director of FDA's Center for Biologics Evaluation and Research.

Men and women are equally affected by vWD, which is caused by a deficiency or defect in certain plasma proteins critical to blood clotting. In most affected people, the disease is mild, and treatment usually is not required to stop bleeding. However, about 2,000 people in the U.S. each year suffer from moderate and severe forms of the disease in which bleeding can be excessive if not treated.

Successful management of surgery or invasive procedures in mildly, moderately and severely affected individuals routinely requires correction of the bleeding defect. In the absence of correction of the bleeding defect, patients may suffer from prolonged bleeding and delayed wound healing.

Alphanate is purified from pooled human plasma from carefully screened and tested U.S. donors, and contains the clotting proteins deficient or def
'"/>




Page: 1 2

Related medicine news :

1. FDA Approves Contraceptive Ring
2. FDA Approves New HIV Drug, Viread
3. FDA Approves Birth Control Skin Patch
4. FDA Approves New Arthritis Drug, Bextra
5. FDA Approves Elidel Cream for Eczema
6. FDA Approves New Anti-Clotting Drug
7. FDA Approves New surgery Treatment for Farsightedness
8. FDA Approves Anti-Cancer Cell Drug - Zevalin
9. FDA Approves Remodulin for Pulmonary Hypertension
10. World Health Organisation Takes a Historic Decision and Approves Treaty to Discourage Smoking
11. World Health Organisation Takes a Historic Decision and Approves Treaty to Discourage Smoking
Post Your Comments:
Breaking Medicine News(10 mins):Health News:Delinquent boys at increased risk of premature death and disability by middle age 2Health News:Delinquent boys at increased risk of premature death and disability by middle age 3Health News:Nutra Pharma Completes FDA Submission for Nyloxin OTC and Nyloxin Rx -- Over-the-Counter and Prescription Treatments for Chronic Pain 2Health News:Nutra Pharma Completes FDA Submission for Nyloxin OTC and Nyloxin Rx -- Over-the-Counter and Prescription Treatments for Chronic Pain 3Health News:Kroll Fraud Solutions to Host Webinar for Healthcare Organizations on Achieving HITECH Compliance 2Health News:Kroll Fraud Solutions to Host Webinar for Healthcare Organizations on Achieving HITECH Compliance 3Health News:New Blood Thinner Could Replace Warfarin to Fight Venous Clots 2Health News:New Blood Thinner Could Replace Warfarin to Fight Venous Clots 3Health News:New Data Support Long-term Use of Antiepileptic Drug Vimpat(R) (Lacosamide) (C-V) 2Health News:New Data Support Long-term Use of Antiepileptic Drug Vimpat(R) (Lacosamide) (C-V) 3Health News:New Data Support Long-term Use of Antiepileptic Drug Vimpat(R) (Lacosamide) (C-V) 4Health News:New Data Support Long-term Use of Antiepileptic Drug Vimpat(R) (Lacosamide) (C-V) 5Health News:New Data Support Long-term Use of Antiepileptic Drug Vimpat(R) (Lacosamide) (C-V) 6Health News:New Data Support Long-term Use of Antiepileptic Drug Vimpat(R) (Lacosamide) (C-V) 7Health News:New Data Support Long-term Use of Antiepileptic Drug Vimpat(R) (Lacosamide) (C-V) 8Health News:New Data Support Long-term Use of Antiepileptic Drug Vimpat(R) (Lacosamide) (C-V) 9Health News:New Data Support Long-term Use of Antiepileptic Drug Vimpat(R) (Lacosamide) (C-V) 10Health News:New Data Support Long-term Use of Antiepileptic Drug Vimpat(R) (Lacosamide) (C-V) 11
Breaking Medicine Technology:Elusys Presents Data From Anthim(R) Anthrax Anti-Toxin Studies at the HHS Stakeholders Workshop 2009 & BARDA Industry Day 2Elusys Presents Data From Anthim(R) Anthrax Anti-Toxin Studies at the HHS Stakeholders Workshop 2009 & BARDA Industry Day 3New Research Shows a Vitamin/Nutriceutical Formulation Improves Memory and Cognitive Performance in Community-Dwelling Adults 2Merieux Alliance Becomes Institut Merieux 2Merieux Alliance Becomes Institut Merieux 3Merieux Alliance Becomes Institut Merieux 4Patients Beyond Borders Thailand Edition to Launch in September 51610 1Patients Beyond Borders Thailand Edition to Launch in September 51610 2Patients Beyond Borders Thailand Edition to Launch in September 51610 3OraVerse 28R 29 Selected by Dentistry Today Magazine as One of the Top 100 Products of 2009 51608 1OraVerse 28R 29 Selected by Dentistry Today Magazine as One of the Top 100 Products of 2009 51608 2OraVerse 28R 29 Selected by Dentistry Today Magazine as One of the Top 100 Products of 2009 51608 3Julie Stav Reminds Hispanic Moms to Invest in Their Familys Wellness with Milk 21 51606 1Julie Stav Reminds Hispanic Moms to Invest in Their Familys Wellness with Milk 21 51606 2Julie Stav Reminds Hispanic Moms to Invest in Their Familys Wellness with Milk 21 51606 3